ÂÜÀòÂÒÂ×

Che-Wei Chang is a Principal Scientist at BridgeBio since September 2021, leading preclinical research focused on developing novel drugs for diseases with unmet needs. With extensive expertise in various modalities, Che-Wei formulates overall preclinical strategies, manages a diverse team of scientists, and establishes both cell-based and cell-free assays. Previous experience as a Postdoctoral Fellow at Gladstone Institutes involved studying the role of tau in neurological diseases, publishing in high-profile journals, and leading multidisciplinary research projects. Che-Wei also completed postdoctoral work at the University of Wisconsin-Madison, investigating synaptophysin dynamics, and obtained a Ph.D. in Neuroscience from the same institution. Prior education includes a Master's and Bachelor's degree from National Taiwan University.